Pfizer – Real World Evidence on Early Use of Aztreonam-Avibactam

Source-based overview

Pfizer – Real World Evidence on Early Use of Aztreonam-Avibactam is a research grant from Pfizer. Research call on early and appropriate use of aztreonam-avibactam. It focuses on Antimicrobial resistance; real-world evidence and is relevant to Australia; Brazil; Chile; India; Italy; South Africa; Spain; UK. The recorded deadline or key date is Released 30 Sep 2026; closes 25 Nov 2026. Applicants should review the official page for the complete eligibility rules, required documents, assessment criteria, funding conditions, deadline time zone and submission route.

Eligibility

Eligible applicants and locations: Australia; Brazil; Chile; India; Italy; South Africa; Spain; UK. Confirm any institutional, citizenship, career-stage and partnership requirements on the official call page.

Funding and benefits

Per RFP

See the official call page for funding and support details

Themes and supported activities

Antimicrobial resistance; real-world evidence

Research Grant

Australia; Brazil; Chile; India; Italy; South Africa; Spain; UK

Deadline and timeline

Released 30 Sep 2026; closes 25 Nov 2026: Released 30 Sep 2026; closes 25 Nov 2026: Nov 25, 2026.

Applicants should confirm the exact deadline time, time zone, required documents, portal steps and any institutional approvals on the official call page before submitting.

How to apply

Open the official call page, confirm the current requirements and deadline time zone, prepare the requested documents and submit through the funder or organiser's stated route.

Before applying, check eligibility rules, budgets, attachments, page limits, partner requirements, cost-share conditions and whether the opportunity uses an expression of interest, full proposal, registration or nomination stage.